{
    "Trade/Device Name(s)": [
        "VITROS Immunodiagnostic Products CK-MB Reagent Pack",
        "VITROS CK-MB Assay"
    ],
    "Submitter Information": "Ortho Clinical Diagnostics",
    "510(k) Number": "K212648",
    "Predicate Device Reference 510(k) Number(s)": [
        "K993068"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JHX"
    ],
    "Summary Letter Date": "September 23, 2021",
    "Summary Letter Received Date": "September 28, 2021",
    "Submission Date": "January 27, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine Phosphokinase/Creatine Kinase Or Isoenzymes Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "CK-MB",
        "Creatine phosphokinase",
        "Creatine kinase isoenzymes"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (Heparin)"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VITROS 3600 Immunodiagnostic System"
    ],
    "Method(s)/Technology(ies)": [
        "Immunometric immunoassay",
        "Luminescent detection"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Pack",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for VITROS Immunodiagnostic Products CK-MB Reagent Pack, an immunometric immunoassay for quantitative CK-MB measurement on VITROS 3600 system",
    "Indications for Use Summary": "For in vitro quantitative measurement of CK-MB in human serum and plasma (EDTA or heparin) to aid in diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy",
    "fda_folder": "Clinical Chemistry"
}